Journal
MOLECULAR CELL
Volume 12, Issue 1, Pages 167-176Publisher
CELL PRESS
DOI: 10.1016/S1097-2765(03)00245-4
Keywords
-
Categories
Funding
- NIAID NIH HHS [AI40847] Funding Source: Medline
- NIGMS NIH HHS [GM 62437] Funding Source: Medline
Ask authors/readers for more resources
The HIV transcriptional activator Tat is acetylated by p300 at a single lysine residue in the TAR RNA binding domain. We have generated monoclonal and polyclonal antibodies specific for the acetylated form of Tat (AcTat). Microinjection of anti-AcTat antibodies inhibited Tat-mediated transactivation in cells. Similarly, the p300 inhibitor Lys-CoA and siRNA specific for p300 suppressed Tat transcriptional activity. Full-length synthetic AcTat bound to TAR RNA with the same affinity as unacetylated Tat, but formation of a Tat-TAR-CyclinT1 ternary complex was completely inhibited in the presence of AcTat. We propose that Tat acetylation may help in dissociating the Tat cofactor CyclinT1 from TAR RNA and serve to transfer Tat onto the elongating RNA polymerase II.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available